Entrada Therapeutics, Inc.

NasdaqGM:TRDA Rapporto sulle azioni

Cap. di mercato: US$581.3m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Entrada Therapeutics Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dipal Doshi

Amministratore delegato

US$3.7m

Compenso totale

Percentuale dello stipendio del CEO15.7%
Mandato del CEO7yrs
Proprietà del CEO0.3%
Durata media del management4yrs
Durata media del Consiglio di amministrazione3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dipal Doshi rispetto agli utili di Entrada Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$104m

Mar 31 2024n/an/a

US$23m

Dec 31 2023US$4mUS$585k

-US$7m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$3mUS$565k

-US$95m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$6mUS$425k

-US$51m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$906kUS$385k

-US$27m

Compensazione vs Mercato: La retribuzione totale di Dipal ($USD 3.74M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Dipal è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Dipal Doshi (48 yo)

7yrs

Mandato

US$3,735,466

Compensazione

Mr. Dipal Doshi serves as Director of The Children's Health Fund. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics, Inc. since August 2017 and served as President since Augus...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Dipal Doshi
CEO & Director7yrsUS$3.74m0.33%
$ 1.9m
Nathan Dowden
President & COO4.8yrsUS$1.49m0.027%
$ 155.3k
Natarajan Sethuraman
Chief Scientific Officer6.9yrsUS$1.49m0.31%
$ 1.8m
Kory Wentworth
CFO & Treasurer3.8yrsNessun dato0.23%
$ 1.3m
Jared Cohen
General Counsel4.3yrsNessun datoNessun dato
Kerry Robert
Senior Vice President of People3yrsNessun datoNessun dato
Karla MacDonald
Chief Corporate Affairs Officer2.1yrsNessun datoNessun dato
Kevin Healy
Senior Vice President of Regulatory Affairsless than a yearNessun datoNessun dato

4.0yrs

Durata media

50.5yo

Età media

Gestione esperta: Il team dirigenziale di TRDA è considerato esperto (durata media dell'incarico 4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dipal Doshi
CEO & Director7yrsUS$3.74m0.33%
$ 1.9m
Peter Kim
Director3.7yrsUS$192.12k0.30%
$ 1.7m
Mary Thistle
Industry Leader & Independent Director3.3yrsUS$211.18k0%
$ 0
Kush Parmar
Independent Chairman of the Board7.8yrsUS$237.58k0%
$ 0
Bernhardt G. Zeiher
Industry Leader & Independent Director1.3yrsUS$334.02k0%
$ 0
Gina Chapman
Independent Directorless than a yearUS$341.88k0%
$ 0

3.5yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TRDA sono considerati esperti (durata media dell'incarico 3.5 anni).